Hcw Biologics Inc

This proposal seeks stockholder approval under Nasdaq Listing Rule 5635(d) (the “Nasdaq 20% Rule”) to permit the issuance of Common Stock upon exercise of Common Warrants issued in a July 29, 2026 private placement. The Company entered into a Securities Purchase Agreement and issued units that include Common Warrants exercisable for up to 618,682 shares; absent stockholder approval the Company would be restricted from issuing shares upon exercise to the extent such issuance would exceed 19.99% of outstanding shares (the Exchange Cap). Management is seeking approval to preserve the economic terms of the private placement and to ensure that investors can exercise their warrants in accordance with the Transaction Documents, which supports the Company’s financing strategy. The board’s recommendation to vote FOR is framed as a compliance and financing-enablement measure: approval removes a Nasdaq-imposed limitation that would otherwise limit warrant exercises and the potential capital that could otherwise be realized. If approved, warrant holders may exercise and receive up to 618,682 shares, which will dilute existing holders proportionally but provide potential capital and investor confidence tied to the Offering. If not approved, the warrants will remain outstanding but will be effectively capped at the Exchange Cap, reducing the likelihood of receiving expected capital upon exercise and limiting the financing benefits anticipated from the Offering. The proposal is transaction-specific and not a general authorization to issue additional securities; it responds to a Nasdaq rule designed to protect investors by requiring shareholder approval for dilutive issuances at below-market prices that meet the 20% threshold. In evaluating this proposal, an analyst should weigh the immediate dilutive effect against the capital and strategic benefits the Company expects to realize from the Offering and consider the company’s current liquidity, capital needs, and alternative financing options. The vote required is a majority of votes cast, and broker non-votes and abstentions will not affect the outcome if treated as a “votes cast” matter; the Company has disclosed the practical consequences both if approved and if not approved.

This proposal would amend and restate the Company’s 2021 Equity Incentive Plan to add a 2,500,000-share Special Reserve and remove the plan’s prior automatic annual share-increase (evergreen) feature. Management describes the current problem as historically issued options now being significantly underwater and recent reverse stock splits having materially reduced the share pool available for compensation; the Special Reserve is intended to restore the Company’s ability to grant equity-based incentives. The Special Reserve is structured as five increments of 500,000 shares each, released only upon certification that the Company’s sustained Nasdaq closing price has reached specified milestones (first milestone $5.00 sustained for 20 trading days, then escalating to $10, $20, $40 and $80), making awards explicitly performance- and value-driven. Awards from the reserve would be discretionary, conditioned on achievement of share-price milestones, have exercise prices at or above the then-applicable market price, and vest over service periods of one to two years, which the Board argues aligns employee rewards with shareholder value creation. The Board’s recommendation to vote FOR emphasizes retention, recruitment, alignment of management and employee incentives with shareholder returns, and preserving cash in a challenging financing environment—factors management says are necessary to retain talent and continue operations while pursuing clinical and R&D objectives. Approval would materially increase potential dilution (the Share Pool would become 2,515,704 shares inclusive of prior grants), and investors should evaluate the dilution against anticipated improvements in operating performance and the Company’s ability to maintain Nasdaq listing and execute its clinical programs. If not approved, the Amended Plan and Special Reserve will not become effective, and contingent awards tied to the Special Reserve will not be grantable, constraining the Company’s compensation flexibility and potentially hampering recruitment/retention efforts. From a governance perspective, the Special Reserve contains safeguards—no discounted options, outside director limits, no reloads, milestone gating and fixed reserve size unless further shareholder approval is obtained—which may mitigate some dilution concerns but still represent a significant potential expansion of the equity pool. Analysts should consider the company’s historical equity usage, the low current share availability (15,704 shares remaining as of Aug 31, 2026), the backdrop of reverse splits and financing challenges, and the performance milestones’ stringency when assessing the trade-off between dilution and incentive alignment.

This catch-all proposal reserves the meeting for any additional matters that may properly be brought before stockholders, although the Company states it has not received any stockholder proposals in advance and that the bylaws require advance notice for such proposals. The proxy materials make clear that the Board’s solicited proxies will have discretionary authority to vote on any other matters if properly presented, meaning that in practice the board-appointed proxies will decide such items unless a stockholder has timely provided notice and the Company accepts the proposal for inclusion. The Company states that its bylaws require advance notice and that none were received, which reduces the likelihood of substantive additional matters being presented but does not preclude adjournment- or procedural-related items. From a governance and shareholder-rights perspective, analysts should note the company’s statement that proxies will use their judgment to vote on unspecified items, which is standard practice but places de facto control over unexpected agenda items with management and the board. If any new substantive proposal did arise, the Company’s description suggests the board could consider it and instruct its proxies accordingly, potentially creating outcomes not explicitly recommended in these proxy materials. The practical risk to shareholders is limited given the advance-notice requirement and the Company’s explicit representation that no other matters are known to be pending, but investors should remain attentive to the proxy and meeting report to confirm whether any additional items were in fact presented and how proxies were voted. For completeness, the Company will announce preliminary results at the meeting and file final results on Form 8-K within four business days, which will disclose any other matters voted upon and the board proxies’ actions. In evaluating any ad hoc matter that might appear, long-term investors should weigh whether the item is likely to be procedural (e.g., adjournment) versus substantive (e.g., a new financing or amendment) and consider engaging with the company if concerned.